spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  carcinoid syndrome 

 HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2017
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 1 Jul 2014
Ipsen submits marketing authorization applications in the US and Europe for Somatuline(R) (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2013
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2012
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Mar 2011
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2009
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Jun 2008
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2008
Callisto Pharmaceuticals Amends and Restates Atiprimod License Agreement with Genzyme
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 May 2006
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
carcinoid syndrome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.